PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
PVCT.WS was delisted on the 13th of October, 2016.
4 hedge funds and large institutions have $149K invested in PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
73% less capital invested
Capital invested by funds: $547K → $149K (-$398K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$579 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $114K | – | – | – |
|
2
Millennium Management
New York
| $26K | – | – | – |
|
3
Creative Planning
Overland Park,
Kansas
| $8K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $1K | +$579 | +4,390 | +79% |
|
PVCT.WS Hedge Fund Activity: Q3 2016 in Review
4 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) (PVCT.WS) for Q3 2016, worth a combined $149K — down 73% from $547K a quarter earlier.
Fund positioning in PVCT.WS was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $579.
- 4 institutional investors held PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) (PVCT.WS) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $149K of PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) stock for Q3 2016, down 73% quarter-over-quarter.
- 0 funds opened new PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) positions in Q3 2016 and 0 closed out.
- The largest PROVECTUS BIOPHARMACEUTICALS INC WTS (DE) buyer in Q3 2016 was UBS Group, an estimated $579 added.
Based on aggregated 13F filings for Q3 2016.